Clarivate Plc (CLVT) Quarterly and Annual Segment Results by Country and Region - CSIMarket
CSIMarket
 
Clarivate Plc  (NYSE: CLVT)

Select the Financial Report: Select the Period:


Description of Clarivate Plc's Business Segments


Clarivate Plc is a global leader in providing expert solutions and insights that empower innovation and drive discovery across various sectors. With a diverse portfolio of segments, products, and services, Clarivate addresses the complex needs of researchers, intellectual property professionals, life sciences organizations, and academic institutions.

Segments:

1. Scientific and Academic Research Solutions:
This segment is dedicated to supporting academic institutions, researchers, and organizations by providing tools to analyze and navigate the complexities of scientific literature and research data. Clarivate’s offerings in this area assist in:
- Data extraction and evaluation from global research publications.
- Providing access to the Web of Science, a comprehensive database featuring journals, articles, conference proceedings, and patents, complemented by citation indices that track the impact of research.
- Dedicated consulting services that guide institutions on improving their research strategy, funding acquisition, author placement, and publication practices.
This segment serves a robust network of over 8,500 institutions and 40 million researchers globally.

2. Intellectual Property Solutions:
This segment focuses on providing analytics and insights that help companies safeguard and manage their intellectual property portfolios effectively. Key offerings include:
- Tools for trademark research, allowing firms to assess potential obstacles and strategies for new marks.
- Databases and examination services designed to streamline the trademark process and ensure compliance with regulations.
- Advisory services that help companies navigate intellectual property laws and optimize their IP strategies.

3. Pharmaceutical and Life Sciences Solutions:
Geared toward the pharmaceutical industry and life sciences, this segment offers technologies and data solutions to enhance drug discovery and development processes. Noteworthy components include:
- Cortellis, which provides vital insights into drug development timelines, clinical trials, regulatory evaluations, and market access strategies.
- Predictive analytics tools that enable pharmacies and research institutions to conduct more informed research and development activities.
- Data management and visualization tools that synthesize vast amounts of information to aid decision-making.

4. Patents Solutions:
Clarivate’s patent offerings encompass a range of services designed to enhance understanding and management of patent rights. This includes:
- Comprehensive databases that aggregate patent data from around the world.
- Analytical tools and platforms for conducting thorough patent searches and competitive analysis.
- Patent drafting software and services that aid firms in preparing and filing patents effectively and efficiently.
- Prosecution services that ensure compliance and efficacy in the patent application process.

Products:

1. Web of Science:
A premier online research platform aggregating scientific literature across disciplines. It provides researchers with comprehensive access to:
- Citation data to measure the impact and relevance of publications.
- Tools for citation mapping and networking with fellow researchers.
- Advanced research analytics capabilities to evaluate trends and collaborations.

2. Derwent Innovation:
This patent analytics platform is fundamental in helping organizations assess the depth and breadth of patent portfolios. Features include:
- Analysis tools for understanding competitive landscapes and technology trends.
- Patent drafting tools that streamline the creation of patent applications.
- Services for patent prosecution to guide clients through the legal intricacies of obtaining patents.

3. Cortellis:
A life sciences intelligence suite that delivers critical insights into the pharmaceutical landscape. It offers:
- Comprehensive data on drug development phases, clinical trials, and associated regulatory filings.
- Predictive analytics that offer forecasts on drug success and market viability.
- Real-time alerts that keep teams informed of pivotal changes in the marketplace.

4. CompuMark:
A dedicated trademark research platform providing tools for comprehensive trademark assessments. Key functionalities include:
- Extensive search capabilities to identify existing trademarks and potential conflicts.
- Monitoring services that keep track of competitor activities and changes in the trademark landscape.
- Prosecution services assisting with filings and responses to oppositions.

Services:

1. Scientific Consulting Services:
Tailored consulting for researchers and institutions aimed at addressing complex research challenges. This includes strategic advice on:
- Grant applications and funding opportunities.
- Optimal research design methodologies and effective publication strategies.

2. Intellectual Property Services:
Clarivate provides a suite of services focused on enhancing the management of IP assets, which encompass:
- Patent drafting and strategic prosecution services to navigate challenges in obtaining patents.
- Comprehensive trademark search and registration services to protect brand identities.
- Ongoing monitoring of trademarks to anticipate and mitigate potential infringements.

3. Life Sciences Analytics Services:
Custom analytics offerings that inform decision-making for life sciences companies, covering:
- Tailored data analyses regarding drug development trends and clinical trial outcomes.
- Regulatory compliance consulting to navigate the complex landscape of drug approvals and market entry.

4. Research Analytics Services:
Services designed to drive insights into scientific research trends through:
- Citation studies that illuminate pathways for potential collaboration.
- Analytical frameworks that provide comprehensive overviews of an entitys research footprint and international standing in scientific communities.

Through these segments, products, and services, Clarivate Plc stands at the forefront of empowering innovation in science and business, ensuring stakeholders have access to the critical insights and data necessary for success in their respective fields.


Composition of Clarivate Plc Revenues by Segments

 
Subscription revenues    136.77 % of total Revenue
Re-occurring    18.55 % of total Revenue
Recurring    86.44 % of total Revenue
Transactional and other revenues    13.56 % of total Revenue
Academia Government    50.38 % of total Revenue
Intellectual Property    33.68 % of total Revenue
Life Sciences Healthcare    15.94 % of total Revenue
Re-occurring Revenues    37.22 % of total Revenue
Recurring Revenues    173.99 % of total Revenue
Transactional Revenues    26.32 % of total Revenue
Academia & Government Group    101.67 % of total Revenue
Intellectual Property Group    67.55 % of total Revenue
Life Sciences and Healthcare Group    31.08 % of total Revenue

Q1 three months ended (Mar 31 2026)
Revenues by Business Segments Revenues
(in millions $)
%
(of total Revenues)
Subscription revenues 800.80 136.77 %
Re-occurring 108.60 18.55 %
Recurring 506.10 86.44 %
Transactional and other revenues 79.40 13.56 %
Academia Government 295.00 50.38 %
Intellectual Property 197.20 33.68 %
Life Sciences Healthcare 93.30 15.94 %
Total 585.50 100 %
Re-occurring Revenues 217.90 37.22 %
Recurring Revenues 1,018.70 173.99 %
Transactional Revenues 154.10 26.32 %
Academia & Government Group 595.30 101.67 %
Intellectual Property Group 395.50 67.55 %
Life Sciences and Healthcare Group 182.00 31.08 %




Q1 three months ended (Mar 31 2026)
Revenue Growth rates by Segment Y/Y Revenue
%
Q/Q Revenue
%
Subscription revenues 106.07 % -
Re-occurring 2.55 % -
Recurring 2.35 % -
Transactional and other revenues -19.96 % -
Academia Government -2.54 % -
Intellectual Property 2.34 % -
Life Sciences Healthcare -5.09 % -
Total -1.38 % -76.15 %
Re-occurring Revenues - -
Recurring Revenues - -
Transactional Revenues - -
Academia & Government Group - -
Intellectual Property Group - -
Life Sciences and Healthcare Group - -




Q1 three months ended (Mar 31 2026)
Income by Business Segments Income
(in millions $)
%
(Profit Margin)
Total -40.20 -




Q1 three months ended (Mar 31 2026)
Income Growth rates by Segment Y/Y Income
%
Q/Q Income
%
Total - -




Annual Report on Clarivate Plc Divisions, Sales by Country

 
Subscription revenues   Subscription revenues Segment contribution to total sales 65.39 % of total Revenue
Re-occurring   Re-occurring Segment contribution to total sales 17.68 % of total Revenue
Recurring   Recurring Segment contribution to total sales 83.08 % of total Revenue
Transactional and other revenues   Transactional and other revenues Segment contribution to total sales 16.92 % of total Revenue
Academia Government   Academia Government Segment contribution to total sales 51.56 % of total Revenue
Intellectual Property   Intellectual Property Segment contribution to total sales 32.56 % of total Revenue
Life Sciences Healthcare   Life Sciences Healthcare Segment contribution to total sales 15.88 % of total Revenue
North America   North America Segment contribution to total sales 53.07 % of total Revenue
EMEA   EMEA Segment contribution to total sales 26.67 % of total Revenue
Asia Pacific   Asia Pacific Segment contribution to total sales 20.26 % of total Revenue
Noncurrent assets   Noncurrent assets Segment contribution to total sales 0.76 % of total Revenue


Twelve months ended 2025
CLVT s Annual Revenue by Geography and Business Segments Sales
(in millions $)
%
(of total Sales)
Subscription revenues 1,605.50 65.39 %
Re-occurring 434.20 17.68 %
Recurring 2,039.70 83.08 %
Transactional and other revenues 415.50 16.92 %
Academia Government 1,266.00 51.56 %
Intellectual Property 799.40 32.56 %
Life Sciences Healthcare 389.80 15.88 %
Total 2,455.20 100 %
North America 1,303.00 53.07 %
EMEA 654.80 26.67 %
Asia Pacific 497.40 20.26 %
Noncurrent assets 18.70 0.76 %


Twelve months ended 2025
CLVT s Annual Income by Country and Business Segments Income
(in millions $)
%
(Profit Margin)
Total -201.10 -

Twelve months ended 2025
Annual Revenue and Income Growth by Country and Business Segments % Y/Y Sales Growth % Y/Y Income Growth
Subscription revenues -1.31 % -
Re-occurring 1.02 % -
Recurring -0.82 % -
Transactional and other revenues -16.92 % -
Academia Government -4.55 % -
Intellectual Property -1.48 % -
Life Sciences Healthcare -6.95 % -
Total -3.97 % -
North America -5.68 % -
EMEA -1.95 % -
Asia Pacific -1.99 % -
Noncurrent assets -12.62 % -



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.